Abstract
Recent years have seen the development of the concept of combination therapy for treating severe fungal sepsis. The advantages of this approach are a potential improvement in patient survival and a reduction in the chance of resistance developing to each of the single agents. The disadvantage is that combining drugs may increase the chance of toxicity. Mycograb® is a genetically recombinant antibody against fungal heat shock protein 90 (hsp90) which is poised to become the mainstay of combination therapy. This paper presents data on how hsp90 is important to fungi and what role it might play in human disease with possible interactions with interleukin 6 and nitric oxide. There is discussion of preclinical data demonstrating synergy in vitro between Mycograb® and amphotericin B and caspofungin. The progress of Mycograb® through a Phase II pharmacokinetic study when used in escalating doses with a liposomal amphotericin B preparation has also been reviewed. The concepts behind a Phase II pivotal study, where Mycograb® or a placebo was given in combination with a liposomal amphotericin B drug for five days for the treatment of disseminated candidiasis are discussed.
Keywords: mycograb, hsp, candidiasis, amphotericin b, interleukin, map kinases, nitric oxide, immunotherapy
Current Molecular Medicine
Title: Human Recombinant Antibody to HSP90: A Natural Partner in Combination Therapy
Volume: 5 Issue: 4
Author(s): R. C. Matthews and J. P. Burnie
Affiliation:
Keywords: mycograb, hsp, candidiasis, amphotericin b, interleukin, map kinases, nitric oxide, immunotherapy
Abstract: Recent years have seen the development of the concept of combination therapy for treating severe fungal sepsis. The advantages of this approach are a potential improvement in patient survival and a reduction in the chance of resistance developing to each of the single agents. The disadvantage is that combining drugs may increase the chance of toxicity. Mycograb® is a genetically recombinant antibody against fungal heat shock protein 90 (hsp90) which is poised to become the mainstay of combination therapy. This paper presents data on how hsp90 is important to fungi and what role it might play in human disease with possible interactions with interleukin 6 and nitric oxide. There is discussion of preclinical data demonstrating synergy in vitro between Mycograb® and amphotericin B and caspofungin. The progress of Mycograb® through a Phase II pharmacokinetic study when used in escalating doses with a liposomal amphotericin B preparation has also been reviewed. The concepts behind a Phase II pivotal study, where Mycograb® or a placebo was given in combination with a liposomal amphotericin B drug for five days for the treatment of disseminated candidiasis are discussed.
Export Options
About this article
Cite this article as:
Matthews C. R. and Burnie P. J., Human Recombinant Antibody to HSP90: A Natural Partner in Combination Therapy, Current Molecular Medicine 2005; 5 (4) . https://dx.doi.org/10.2174/1566524054022594
DOI https://dx.doi.org/10.2174/1566524054022594 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Identification of a Novel Inhibitor of the NF-κB Pathway
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Anti-Inflammatory and Antioxidant Properties of Piper Species: A Perspective from Screening to Molecular Mechanisms
Current Topics in Medicinal Chemistry Prospects for Anti-Neoplastic Therapies Based on Telomere Biology
Current Cancer Drug Targets Astroglial Connexins in Neurological and Neuropsychological Disorders and Radiation Exposure
Current Medicinal Chemistry 2-Arylindoles: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activity
Current Medicinal Chemistry Carbon Monoxide and the Brain: Time to Rethink the Dogma
Current Pharmaceutical Design Nicotinamide Phosphoribosyltransferase (Nampt): A Link Between NAD Biology, Metabolism, and Diseases
Current Pharmaceutical Design Microbubbles as a Vehicle for Gene and Drug Delivery: Current Clinical Implications and Future Perspectives
Current Pharmaceutical Design Letter to the Editor: The Versatility of Tumor Suppressor Proteins and its Therapeutic Potential
Protein & Peptide Letters Endothelial Activation. Sliding Door to Atherosclerosis
Current Pharmaceutical Design Ceramide: Therapeutic Potential in Combination Therapy for Cancer Treatment
Current Drug Metabolism Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line
Current Drug Delivery Prognostic Factors after R0 Resection of Colorectal Cancer Liver Metastases: A Systematic Review and Pooled-Analysis
Reviews on Recent Clinical Trials Recent Patents on Oral Vaccine Design
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Design and Synthesis of Mannich bases as Benzimidazole Derivatives as Analgesic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Protein-Protein Interactions: Recent Progress in the Development of Selective PDZ Inhibitors
Current Chemical Biology Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Ustekinumab-induced Sarcoidosis in a Patient with Psoriatic Arthritis
Current Drug Safety Changes of Expression of the Protein C Pathway Components in LPSInduced Endotoxemia–Implication for Sepsis
Cardiovascular & Hematological Disorders-Drug Targets